BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31988437)

  • 1. Disease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemia.
    Gazeau N; Derrieux C; Nibourel O; Berthon C; Grardel N; Goursaud L; Boyer T; Dumezy F; Coiteux V; Quesnel B; Preudhomme C; Roche-Lestienne C; Duployez N
    Leukemia; 2020 Aug; 34(8):2230-2233. PubMed ID: 31988437
    [No Abstract]   [Full Text] [Related]  

  • 2. BCR/ABL1 Kinase Domain Mutation Monitoring: Could Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Benefit As Well?
    Andolina JR
    Acta Haematol; 2015; 134(2):69-70. PubMed ID: 25895547
    [No Abstract]   [Full Text] [Related]  

  • 3. Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
    Piccaluga PP; Paolini S; Martinelli G
    Cancer; 2007 Sep; 110(6):1178-86. PubMed ID: 17701954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
    Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
    Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia.
    Pavlovsky C; Chan O; Talati C; Pinilla-Ibarz J
    Future Oncol; 2019 Jan; 15(3):257-269. PubMed ID: 30251548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant.
    Samra B; Kantarjian HM; Sasaki K; Alotaibi AS; Konopleva M; O'Brien S; Ferrajoli A; Garris R; Nunez CA; Kadia TM; Short NJ; Jabbour E
    Acta Haematol; 2021; 144(3):285-292. PubMed ID: 33238261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute.
    Kidoguchi K; Ureshino H; Kizuka-Sano H; Yamaguchi K; Katsuya H; Kubota Y; Ando T; Miura M; Takahashi N; Kimura S
    Int J Hematol; 2021 Aug; 114(2):199-204. PubMed ID: 33907977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.
    Pfeifer H; Lange T; Wystub S; Wassmann B; Maier J; Binckebanck A; Giagounidis A; Stelljes M; Schmalzing M; Dührsen U; Wunderle L; Serve H; Brück P; Schmidt A; Hoelzer D; Ottmann OG
    Leukemia; 2012 Jul; 26(7):1475-81. PubMed ID: 22230800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three atypical BCR/ABL transcripts detected simultaneously in a Philadelphia-positive acute lymphoblastic leukemia patient showing resistance to tyrosine kinase inhibitors.
    Sun H; Yan Z; Zhang S
    Int J Hematol; 2023 Jan; 117(1):134-136. PubMed ID: 36087225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Philadelphia chromosome-like acute lymphoblastic leukemia: progress in a new cancer subtype.
    Wells J; Jain N; Konopleva M
    Clin Adv Hematol Oncol; 2017 Jul; 15(7):554-561. PubMed ID: 28749919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?
    Short NJ; Kantarjian H; Jabbour E; Ravandi F
    Best Pract Res Clin Haematol; 2017 Sep; 30(3):193-200. PubMed ID: 29050692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case report of a truncated ABL1 mutation in 2 cases with Philadelphia chromosome-positive B cell precursor acute lymphoblastic leukemia.
    Kato K; Takagi S; Takano H; Tsunoda S; Watanabe O; Yamaguchi K; Kageyama K; Kaji D; Taya Y; Nishida A; Ishiwata K; Yamamoto H; Yamamoto G; Asano-Mori Y; Koike Y; Makino S; Wake A; Taniguchi S; Uchida N
    Int J Hematol; 2024 Feb; 119(2):205-209. PubMed ID: 38236369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging BCR/ABL1 Mutations Under Treatment with Tyrosine Kinase Inhibitors in Paediatric Acute Lymphoblastic Leukaemia.
    Molinos-Quintana A; Aquino V; Montero I; Pérez-de Soto C; García-Lozano R; Pérez-Simón JA; Pérez-Hurtado JM
    Acta Haematol; 2015; 134(2):71-5. PubMed ID: 25895602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next-generation sequencing for BCR-ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paper.
    Soverini S; Albano F; Bassan R; Fabbiano F; Ferrara F; Foà R; Olivieri A; Rambaldi A; Rossi G; Sica S; Specchia G; Venditti A; Barosi G; Pane F
    Cancer Med; 2020 May; 9(9):2960-2970. PubMed ID: 32154668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of BCR-ABL1 isoforms on the prognosis of Philadelphia chromosome positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era: A meta-analysis.
    Zhang W; Kuang P; Liu T
    PLoS One; 2020; 15(12):e0243657. PubMed ID: 33338050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.
    Drexler HG; MacLeod RA; Uphoff CC
    Leuk Res; 1999 Mar; 23(3):207-15. PubMed ID: 10071072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Zerbit J; Tamburini J; Goldwirt L; Decroocq J; Cayuela JM; Chapuis N; Contejean A; Batista R; Bouscary D; Willems L
    Leuk Lymphoma; 2021 Dec; 62(14):3558-3560. PubMed ID: 34405773
    [No Abstract]   [Full Text] [Related]  

  • 19. A novel e8a2 BCR-ABL1 fusion with insertion of RALGPS1 exon 8 in a patient with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    McCarron SL; Kelly J; Coen N; McCabe S; Fay M; O'Dwyer M; Hayden PJ; Langabeer SE
    Leuk Lymphoma; 2011 May; 52(5):919-21. PubMed ID: 21338279
    [No Abstract]   [Full Text] [Related]  

  • 20. Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Soverini S; Martelli M; Bavaro L; De Benedittis C; Papayannidis C; Sartor C; Sorà F; Albano F; Galimberti S; Abruzzese E; Annunziata M; Russo S; Stulle M; Imovilli A; Bonifacio M; Maino E; Stagno F; Maria Basilico C; Borlenghi E; Fozza C; Mignone F; Minari R; Stella S; Baccarani M; Cavo M; Martinelli G
    Br J Haematol; 2021 Apr; 193(2):271-279. PubMed ID: 33403687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.